ライフサイエンスコーパス: levofloxacin

1 ent randomization (784 to placebo and 781 to levofloxacin).

2 acin-containing therapy (PPI + amoxicillin + levofloxacin).

3 did not differ significantly from that with levofloxacin.

4 le with poor dentition that was treated with levofloxacin.

5 pp mutant of CO92 and given the same dose of levofloxacin.

6 family Enterobacteriaceae were resistant to levofloxacin.

7 ng women initiated therapy with ofloxacin or levofloxacin.

8 patients who were treated for pneumonia with levofloxacin.

9 e to vancomycin and >90% were susceptible to levofloxacin.

10 e susceptible to penicillin, cefotaxime, and levofloxacin.

11 aluable precursor of the antimicrobial agent Levofloxacin.

12 scular mortality related to azithromycin and levofloxacin.

13 s a key precursor of the antimicrobial agent Levofloxacin.

14 ed to investigate the efficacy and safety of levofloxacin.

15 oxifloxacin, and 1.41 (95% CI, .91-2.18) for levofloxacin.

16 The infection was successfully treated with levofloxacin.

17 0.25 mug/ml), ethambutol (0.25 to 2 mug/ml), levofloxacin (0.12 to 1 mug/ml), moxifloxacin (0.06 to 0

18 ent for the individuals drugs were 99.1% for levofloxacin, 100% for amikacin, 97.4% for capreomycin,

19 ities were the following: ceftazidime, 100%; levofloxacin, 100%; ciprofloxacin, 95.0%; tobramycin, 90

20 (10/31) and 54.5% of patients randomized to levofloxacin (18/33, P = .094) completed prophylaxis.

21 ), ciprofloxacin (264,626 prescriptions), or levofloxacin (193,906 prescriptions).

22 r ciprofloxacin, 2.41 (95% CI, .76-7.68) for levofloxacin, 2.00 (95% CI, 1.06-3.79) for norfloxacin,

23 se rifampin (15 mg per kilogram per day) and levofloxacin (20 mg per kilogram per day) for the first

24 th higher-dose rifampicin (15 mg/kg/day) and levofloxacin (20 mg/kg/day) for the first 8 weeks.

25 fluoroquinolones included 22 of 52 (42%) to levofloxacin, 20 of 54 (37%) to ciprofloxacin, 16 of 47

26 8) for metronidazole, 18% (95% CI 15-22) for levofloxacin, 3% (95% CI 2-5) for amoxicillin, and 4% (9

27 or a 10-day modified sequential therapy with Levofloxacin 500 mg id instead of Clarithromycin (group

28 mg twice daily, amoxicillin 1 g twice daily, levofloxacin 500 mg twice daily, and tinidazole 500 mg t

29 followed by esomeprazole 40 mg twice daily, levofloxacin 500 mg twice daily, and tinidazole 500 mg t

30 1 g/d) for 3 days followed by 7 days of oral levofloxacin (500 mg once daily) and metronidazole (500

31 ducted to compare the efficacy and safety of levofloxacin (500 mg q24h for 9 months) initiated in pat

32 omly assigned to receive a 3-month course of levofloxacin (500 mg/d; n = 76) or placebo (n = 78) star

33 gle-dose azithromycin (500 mg; 106 persons), levofloxacin (500 mg; 111 persons), or rifaximin (1650 m

34 to erythromycin (94.1%) and, less commonly, levofloxacin (54.6%), in addition to beta-lactam agents.

35 88.0%; sulfamethoxazole/trimethoprim, 77.5%; levofloxacin, 58.5%; oxacillin, 54.7%; ciprofloxacin, 51

36 een treatment arms (azithromycin, 3.8 hours; levofloxacin, 6.4 hours; rifaximin, 5.6 hours).

37 bactam (788, 10.3%; 95% CI, 9.6%-11.0%), and levofloxacin (694, 9.1%; 95% CI, 8.5%-9.7%).

38 n, 82%; erythromycin, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; an

39 xacin, 129 microM; gatifloxacin, 130 microM; levofloxacin, 915 microM; and ciprofloxacin, 966 microM.

40 indamycin (98.6%), erythromycin (99.0%), and levofloxacin (99.6%), in addition to beta-lactam agents.

41 the susceptibility rates to clindamycin and levofloxacin according to patient age group.

42 r uveitis, while current first-time users of levofloxacin (adjusted rate ratio, 1.26 [95% CI, 0.90-1.

43 tribution of the pretreated barley straw for levofloxacin adsorption was estimated based on the equil

44 A dose-ranging study with meropenem and levofloxacin alone and in combination against Pseudomona

45 The four drugs studied were levofloxacin, amikacin, capreomycin, and ethionamide.

46 r amoxicillin/clavulanate, erythromycin, and levofloxacin among S. pneumoniae and for trimethoprim/su

47 m (S), 19 to 27 mm (I), and </=18 mm (R) for levofloxacin and >/=25 mm (S), 16 to 24 mm (I), and </=1

48 coccal isolates resistant or intermediate to levofloxacin and 124 pneumococcal isolates susceptible t

49 Ten of 12 laboratories testing levofloxacin and 4 of 4 laboratories testing ofloxacin b

50 The critical concentration established for levofloxacin and amikacin was 1.5 microg/ml, that establ

51 The activities of levofloxacin and clarithromycin against 199 penicillin-

52 Levofloxacin and linezolid were tested as comparator age

53 When concentrations of various antibiotics (levofloxacin and linezolid) are pumped through the chann

54 Bacterial resistant to levofloxacin and meropenem was seen in the control arm.

55 published MIC breakpoints for Salmonella to levofloxacin and ofloxacin, but breakpoints for assignin

56 breakpoints in the MIC zone scattergrams for levofloxacin and ofloxacin, the following disk diffusion

57 d by 1.5-fold for ceftriaxone and 2-fold for levofloxacin and remained the same for vancomycin.

58 to vancomycin (100%), linezolid (>99%), and levofloxacin and tigecycline (both >96%); imipenem susce

59 om 1.0-16.6% for ofloxacin, to 0.5-12.4% for levofloxacin, and 0.9-14.6% for moxifloxacin when tested

60 008 microg/ml) was slightly more active than levofloxacin, and E-test results were generally elevated

61 intermediate to high MICs for moxifloxacin, levofloxacin, and gentamicin were also observed among th

62 patients receiving isoniazid, gatifloxicin, levofloxacin, and moxifloxacin monotherapy.

63 y broth microdilution against ciprofloxacin, levofloxacin, and ofloxacin and by disk diffusion using

64 The MICs for ciprofloxacin, levofloxacin, and ofloxacin were >32 mug/ml for all isol

65 diameters for nalidixic acid, ciprofloxacin, levofloxacin, and ofloxacin were determined for 100 clin

66 2-agent combinations of amikacin, doripenem, levofloxacin, and rifampin were quantitatively assessed

67 ommon (3.8%, 4.4%, and 1.9% in azithromycin, levofloxacin, and rifaximin arms, respectively) (P = .55

68 Single-dose azithromycin, levofloxacin, and rifaximin with loperamide were compara

69 ee new generation quinolones: trovafloxacin, levofloxacin, and sparfloxacin) on the DNA cleavage/reli

70 ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, and trovafloxacin were above the maximal s

71 erial infections, treatment with vancomycin, levofloxacin, and voriconazole prophylaxis resulted in n

72 Both fluorophores and the antibiotic levofloxacin are attached to this bio-orthogonal amino a

73 ted incidence of severe tenosynovitis in the levofloxacin arm (18.2%).

74 luded (31 in the isoniazid arm and 33 in the levofloxacin arm).

75 Treatments were saline (negative control), levofloxacin at 15 mg/kg every 12 h (positive control),

76 Compared with levofloxacin, azithromycin was not inferior (P = .01).

77 s occurred in 81.4%, 78.3%, and 74.8% of the levofloxacin, azithromycin, and rifaximin arms, respecti

78 o compare the efficacy of Clarithromycin and Levofloxacin-based sequential quadruple therapies as fir

79 Ten-day Levofloxacin-based sequential treatment achieved inadequ

80 treatment was significantly higher than with Levofloxacin-based therapy (90%, CI95%: 84-96% vs. 79%,

81 s within the triple therapy; moxifloxacin or levofloxacin-based triple therapy were both associated w

82 cultures were resistant to ciprofloxacin and levofloxacin, but all 15 strains were susceptible to spa

83 Very major discrepancies were not seen with levofloxacin, but occurred with clarithromycin in five s

84 tions for Mycobacterium tuberculosis against levofloxacin by the traditional reference method, agar p

85 (AORs) and 95% confidence intervals (CIs) of levofloxacin, ciprofloxacin, and moxifloxacin compared w

86 In the cases of levofloxacin, ciprofloxacin, and ofloxacin, inhibition o

87 06 to November 2007, outpatient new users of levofloxacin, ciprofloxacin, moxifloxacin, cephalosporin

88 azithromycin, clarithromycin, moxifloxacin, levofloxacin, ciprofloxacin, or amoxicillin-clavulanate

89 Results show that levofloxacin concentrations of 2 microg/ml (BACTEC 460 a

90 was investigated at various temperatures and levofloxacin concentrations, and the activation energy w

91 andomized trial to determine whether a 5-day levofloxacin-containing quadruple concomitant regimen wa

92 Five days of levofloxacin-containing quadruple concomitant therapy is

93 Quadruple Levofloxacin-containing regimens could be an option for

94 adicating H pylori infection than 10 days of levofloxacin-containing sequential therapy.

95 ecommended rescue therapies include PBMT and levofloxacin-containing therapy (PPI + amoxicillin + lev

96 ction site and had an MIC of the pathogen to levofloxacin determined.

97 r quinolones (garenoxacin, gatifloxacin, and levofloxacin, each with a MIC at which 90 percent of the

98 gorical agreements for the ciprofloxacin and levofloxacin Etests were 89.6 and 83.7%, respectively.

99 mized to receive either the oral concomitant levofloxacin, ethambutol, azithromycin, and rifampin (CL

100 A new regimen combining four antibiotics (levofloxacin, ethambutol, azithromycin, and rifamycin) h

101 th ticarcillin, gentamicin and vancomycin or levofloxacin eye drops leading to enucleation in one cas

102 Ceftolozane-tazobactam was non-inferior to levofloxacin for composite cure (306 [76.9%] of 398 vs 2

103 Minor discrepancies were obtained with levofloxacin for one strain (0.5%) by microdilution and

104 In this paper, adsorption of levofloxacin from artificial contaminated water was done

105 ant to the newer fluoroquinolones, including levofloxacin, gatifloxacin, gemifloxacin, and garenoxaci

106 Levofloxacin generated clinical and microbiological resp

107 Levofloxacin, gentamicin, and tetracycline were active a

108 mec-IV strains to clindamycin, erythromycin, levofloxacin, gentamicin, rifampin, minocycline, and tri

109 infection in 15.7 percent of patients in the levofloxacin group and 21.6 percent of patients in the p

110 he mean follow-up time was 46.5 weeks in the levofloxacin group and 46.3 weeks in the placebo group (

111 viruria occurred in 22 patients (29%) in the levofloxacin group and in 26 patients (33.3%) in the pla

112 rapy course, 10.8 percent of patients in the levofloxacin group had at least one febrile episode, as

113 chemotherapy, 3.5 percent of patients in the levofloxacin group had at least one febrile episode, as

114 lates usually sensitive to quinolones in the levofloxacin group vs placebo (14/24 [58.3%] vs 15/45 [3

115 e of ATP was trovafloxacin > ciprofloxacin > levofloxacin > sparfloxacin.

116 s (minimum inhibitory concentration [MIC] to levofloxacin, > or = 0.125 microg/mL) were identified.

117 For levofloxacin, >/=99.0% of strains were susceptible at </

118 estis CO92 and given a subinhibitory dose of levofloxacin had acute inflammation, edema, and masses o

119 Positive control mice (levofloxacin) had 100% survivorship in both neutropenic

120 data support using targeted prophylaxis with levofloxacin in children undergoing induction chemothera

121 Major discrepancies occurred with levofloxacin in one strain (0.5%) by microdilution but w

122 actam led to better responses than high-dose levofloxacin in patients with complicated lower-urinary-

123 To determine the stability of levofloxacin in the two newer test systems (BACTEC 460 a

124 y transplant recipients, a 3-month course of levofloxacin initiated early following transplantation d

125 Prophylactic levofloxacin is effective regardless of age, PS, or tumo

126 stance to metronidazole, clarithromycin, and levofloxacin is more common among H. pylori isolates fro

127 Results show that levofloxacin is stable over the course of testing.

128 High-dose levofloxacin (L) (1,000 mg) was as active as moxifloxaci

129 providing a longer window for initiation of levofloxacin (LEVO) treatment (40 mg/kg).

130 cin (CLI), erythromycin (ERY), gatifloxacin, levofloxacin, linezolid, meropenem, penicillin (PEN), te

131 eatments (Group B, n = 51) and no history of levofloxacin (LVX) consumption were prescribed pantopraz

132 ug resistant TB therapy: moxifloxacin (MXF), levofloxacin (LVX) or gatifloxacin (GFX).

133 Levofloxacin may pose the least risk for uveitis compare

134 loxacin, gatifloxacin, gentamicin, imipenem, levofloxacin, meropenem, tobramycin, and trimethoprim-su

135 We confirmed that the new levofloxacin MIC breakpoints resulted in the highest cat

136 l), ceftriaxone (MIC90s, 0.5 microg/ml), and levofloxacin (MIC90s, < or =0.03 to 0.06 microg/ml).

137 Levofloxacin MICs resulted in a bimodal pattern with val

138 wide, and all patients colonized with FQREC (levofloxacin minimum inhibitory concentration, >/=8 mug/

139 Levofloxacin monotherapy selected for resistance to itse

140 findings were reported regarding the use of levofloxacin/moxifloxacin in the first-line treatment; t

141 We characterized 32 levofloxacin-nonsusceptible Streptococcus pneumoniae (LN

142 Neither the levofloxacin nor the ofloxacin disk yielded good separat

143 romycin of >0.25 mug/ml, and 16% had MICs to levofloxacin of >2 mug/ml.

144 Levofloxacin, oflaxacin, and perfloxacin were most likel

145 ploratory data support offering prophylactic levofloxacin on cycle 1 only of myelosuppressive cancer

146 every 8 h or intravenous high-dose (750 mg) levofloxacin once daily for 7 days.

147 andomly assigned to receive either 500 mg of levofloxacin once daily or matching placebo for seven da

148 ultures showed that the strains resistant to levofloxacin or gatifloxacin were associated with higher

149 07 to 2010, who received intravenous or oral levofloxacin or moxifloxacin.

150 nteers, we confirmed the cross-reactivity of levofloxacin or ofloxacin with these opiate screening as

151 uveitis cases, current use of moxifloxacin, levofloxacin, or ciprofloxacin hydrochloride was compare

152 r rifampin, 97.6% for quinolones (ofloxacin, levofloxacin, or moxifloxacin), 99.2% for amikacin, 99.2

153 to clindamycin, tetracycline, erythromycin, levofloxacin, or mupirocin was detected in a large propo

154 d, placebo-controlled, double-blind trial of levofloxacin (P = .01).

155 Meropenem and levofloxacin penetrations into epithelial lining fluid w

156 Levofloxacin prophylaxis alone reduced these infections,

157 Levofloxacin prophylaxis also minimized the use of treat

158 Levofloxacin prophylaxis of tuberculosis in liver transp

159 ts, 173 received no prophylaxis, 69 received levofloxacin prophylaxis, and 102 received other prophyl

160 mes in patients who received no prophylaxis, levofloxacin prophylaxis, or other prophylaxis during in

161 The combination of levofloxacin-PZA-ethambutol had intermediate bactericida

162 tumors or lymphoma, the prophylactic use of levofloxacin reduces the incidence of fever, probable in

163 Levofloxacin, representative of an important class of fl

164 illin resistance in 10/531 (2%) persons, and levofloxacin resistance in 30/155 (19%) persons; no tetr

165 Levofloxacin resistance increased from 14.3% (2005) to 5

166 alence of metronidazole, clarithromycin, and levofloxacin resistance varied by region.

167 When tested against MSSA, levofloxacin resistance was higher among isolates from p

168 Seventy-eight (96.3%) of the 81 levofloxacin-resistant isolates analyzed possessed multi

169 y tests with a subset of pan-susceptible and levofloxacin-resistant isolates validated the selected t

170 isolates and approximately one-third of the levofloxacin-resistant isolates were multidrug resistant

171 ominant clone with a significant increase in levofloxacin-resistant isolates.

172 The levofloxacin-resistant strains either were isolated from

173 3,133 erythromycin-resistant strains and 81 levofloxacin-resistant strains, were collected from 206

174 e strains while permitting the growth of all levofloxacin-resistant strains.

175 Treatment with intravenous followed by oral levofloxacin resulted in cure.

176 evalence of resistance to clarithromycin and levofloxacin rose significantly over time during the per

177 Ciprofloxacin and levofloxacin susceptibility for all tested pathogens was

178 Levofloxacin susceptibility was determined by broth micr

179 Next, optimum levofloxacin test concentrations were determined for AP,

180 ive antibiotics, amoxicillin, metronidazole, levofloxacin, tetracyclin, and clarithromycin, commonly

181 Levofloxacin, the active l-isomer of the quinolone oflox

182 57 (93%) of 61 isolates were susceptible to levofloxacin (third-generation fluoroquinolone).

183 These findings do not support the use of levofloxacin to prevent posttransplant BK virus infectio

184 Meropenem plus levofloxacin treatment was shown to be a promising combi

185 -generation fluoroquinolone (moxifloxacin or levofloxacin) use and patient mortality, adjusting for r

186 ast, susceptibility rates to clindamycin and levofloxacin varied from 94.0% and 60.7% (aged 6-17 year

187 Levofloxacin was administered as an infusion of 500 mg/h

188 Levofloxacin was associated with an increased risk of ad

189 A 10-day sequential regimen that contains levofloxacin was efficient, safe, and cost saving in era

190 zed trial data, the prophylactic efficacy of levofloxacin was examined for the same subgroups.

191 In contrast, amikacin plus levofloxacin was found to be antagonistic in time-kill s

192 atom in benzene ring attached to fluorine of levofloxacin was investigated by C K-edge X-ray absorpti

193 Susceptibility testing for levofloxacin was performed by Etest.

194 Exposure to levofloxacin was significantly associated with successfu

195 The combination of meropenem plus levofloxacin was synergistic, producing good bacterial k

196 Levofloxacin was used in the subsequent 5 cases, with re

197 A PK curve for an approved antibiotic, levofloxacin, was generated to show utility beyond the f

198 sted ORs for azithromycin, moxifloxacin, and levofloxacin were 2.62 (95% CI, 1.69-4.06), 2.31 (95% CI

199 Meropenem and levofloxacin were administered to partially humanize the

200 ance rates to erythromycin, clindamycin, and levofloxacin were higher in the population aged >/= 65 y

201 whereas resistance rates to clindamycin and levofloxacin were lowest among isolates from patients ag

202 0), media containing subinhibitory levels of levofloxacin were prepared and stored at 4 and 37 degree

203 ant association of current first-time use of levofloxacin with uveitis could not be identified.

204 eneration of PPIs and use of moxifloxacin or levofloxacin within triple therapy as second-line treatm